Mariela Huerta-Rosario
Overview
Explore the profile of Mariela Huerta-Rosario including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
44
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huerta-Rosario M, Mir M, Quispe-Vicuna C, Hwang H, Sarode V, Peng Y, et al.
J Clin Pathol
. 2023 May;
77(8):544-550.
PMID: 37258252
Aims: Touch preparation (TP) and frozen section (FS) are the two methods routinely used in the intraoperative evaluation (IOE) of sentinel lymph nodes (SLNs) to detect metastases in patients with...
2.
Meng D, Yang Q, Jeong M, Curukovic A, Tiwary S, Melick C, et al.
Proc Natl Acad Sci U S A
. 2022 May;
119(20):e2123261119.
PMID: 35561222
Mammalian target of rapamycin complex 1 (mTORC1) senses amino acids to control cell growth, metabolism, and autophagy. Some amino acids signal to mTORC1 through the Rag GTPase, whereas glutamine and...
3.
Sudhan D, Guerrero-Zotano A, Won H, Ericsson P, Servetto A, Huerta-Rosario M, et al.
Cancer Cell
. 2020 Feb;
37(2):258-259.
PMID: 32049049
No abstract available.
4.
Sudhan D, Guerrero-Zotano A, Won H, Ericsson P, Servetto A, Huerta-Rosario M, et al.
Cancer Cell
. 2020 Jan;
37(2):183-199.e5.
PMID: 31978326
We developed neratinib-resistant HER2-mutant cancer cells by gradual dose escalation. RNA sequencing identified TORC1 signaling as an actionable mechanism of drug resistance. Primary and acquired neratinib resistance in HER2-mutant breast...